Stock Market Reviews

Read and share opinions on CELU (Celularity Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
  Oct 30, 2025
• Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
  Oct 14, 2025
• Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
  Sep 3, 2025
• Celularity Second Quarter 2025 Earnings: US$1.02 loss per share (vs US$0.30 loss in 2Q 2024)
  Aug 31, 2025
• Celularity Receives Nasdaq Notice Regarding Form 10-Q
  Aug 22, 2025
• Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
  Aug 18, 2025
• Retail investors among Celularity Inc.'s (NASDAQ:CELU) largest shareholders, saw gain in holdings value after stock jumped 11% last week
  Aug 14, 2025
• Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
  Jul 9, 2025
• Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
  Jul 1, 2025
• Celularity Announces Chief Financial Officer Transition
  Jun 10, 2025
• Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
  Jun 2, 2025
• Celularity Announces Full Year 2024 Operating and Financial Results
  May 9, 2025
• Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
  Apr 25, 2025
• Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
  Apr 14, 2025
• Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
  Apr 7, 2025
• Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
  Feb 25, 2025
• Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
  Feb 24, 2025
• MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs
  Jan 27, 2025
• Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
  Dec 10, 2024
• Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
  Dec 6, 2024